AbbVie Inc. $ABBV is Epoch Investment Partners Inc.’s 6th Largest Position

Epoch Investment Partners Inc. cut its holdings in AbbVie Inc. (NYSE:ABBV) by 9.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,354,248 shares of the company’s stock after selling 142,622 shares during the quarter. AbbVie makes up about 1.8% of Epoch Investment Partners Inc.’s investment portfolio, making the stock its 6th largest position. Epoch Investment Partners Inc.’s holdings in AbbVie were worth $309,432,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Chelsea Counsel Co. purchased a new stake in AbbVie in the third quarter worth about $26,000. Litman Gregory Wealth Management LLC purchased a new stake in AbbVie in the fourth quarter worth about $28,000. Westend Capital Management LLC bought a new position in AbbVie in the fourth quarter worth about $29,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie in the third quarter worth about $31,000. Finally, Legacy Wealth Managment LLC ID raised its holdings in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after purchasing an additional 73 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Stock Up 1.2%

ABBV opened at $227.54 on Friday. AbbVie Inc. has a 52-week low of $181.73 and a 52-week high of $244.81. The company has a market cap of $402.02 billion, a P/E ratio of 112.09, a price-to-earnings-growth ratio of 0.70 and a beta of 0.32. The firm’s 50-day moving average price is $211.05 and its 200-day moving average price is $219.07.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the prior year, the company posted $2.46 earnings per share. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, research analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on ABBV. Piper Sandler boosted their target price on shares of AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. William Blair reiterated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Barclays began coverage on shares of AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 target price for the company. Guggenheim reiterated a “buy” rating and issued a $249.00 target price on shares of AbbVie in a report on Friday, May 1st. Finally, Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price for the company in a report on Thursday, April 30th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.